INDV: Indivior PLC

INDV新闻

• 23:01 Broadcom Inks Pact With Meta, Leads 21 Top Performers Onto Best Stock Watchlists
• 22:25 Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists
• 17:02 MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
• 15:15 ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
• 12:55 Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable
• 08:00 Bull of the Day: Neurocrine Biosciences (NBIX)
• 14:43 IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
• 14:28 Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
• 08:59 Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
• 15:24 IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects
• 13:27 Reasons Why Investors Should Consider Betting on Indivior Stock
• 12:40 5 Small Drug Stocks to Invest in Amid a Biotech Comeback
• 14:13 RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
• 14:05 GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
• 15:07 NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
• 14:59 Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
• 14:52 Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
• 13:58 Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth
• 13:30 Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
• 14:35 BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
• 14:24 PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed
• 13:16 Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome
• 12:14 Can Vertex's Kidney Pipeline Power Its Next Growth Phase?
• 12:04 MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing